Compare WILC & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WILC | STRO |
|---|---|---|
| Founded | 1994 | 2003 |
| Country | Israel | United States |
| Employees | N/A | 133 |
| Industry | Food Distributors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.6M | 524.8M |
| IPO Year | 2001 | N/A |
| Metric | WILC | STRO |
|---|---|---|
| Price | $33.61 | $26.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 2.5K | ★ 305.5K |
| Earning Date | 05-18-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.30 | $0.67 |
| 52 Week High | $37.35 | $43.85 |
| Indicator | WILC | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 47.48 | 40.48 |
| Support Level | $33.00 | $23.43 |
| Resistance Level | $37.13 | $27.96 |
| Average True Range (ATR) | 1.19 | 3.16 |
| MACD | -0.53 | -0.73 |
| Stochastic Oscillator | 14.02 | 17.09 |
G. Willi-Food International Ltd is an Israeli-based company specializing in high-quality, great-tasting kosher food products. The company is engaged, directly and through subsidiaries, in the design, import, marketing and distribution of a variety of over 650 food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Cereals, rice and pastas, and Other Products. The company has one reportable segment: Import- export, marketing and distribution of food products. The majority of the company's revenue is derived from the sale of Dairy and Dairy Substitute Products.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.